Wockhardt will deepen its novel antibiotics pipeline over the next five years and focus on building a biosimilar business for ...

UCB, a global biopharmaceutical company, today announced it will present 24 abstracts from its expansive neurology portfolio, regarding rare epilepsies Dravet syndrome (DS) and Lennox-Gastaut syndrome ...